Study reveals cause of common cancer immunotherapy side effect: Darlinghurst, Sydney Monday, December 2, 2024, 10:00 Hrs [IST] A multinational collaboration co-led by the Garvan I ...

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

Dana-Farber Cancer Institute authors: Giuseppe Tarantino, PhD, David Liu, MD, MPH ...

Discover a recent clinical trial that explored the efficacy of combining pembrolizumab, an anti-PD-1 immunotherapy, with ...

Replimune's BLA submission and promising pipeline drugs are set to impact the global melanoma therapeutics market. Read more ...

Compugen (CGEN) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At 40% ...

Findings indicate a serine/glycine-free diet can reduce colorectal cancer growth and enhance immune response, offering ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies ...

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...

Studying patients with PD-1 or PD-L1 deficiency may help inform new approaches to fine-tuning immunotherapies to maximise ...

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...

PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six ...